In this issue of Cell, Shi and colleagues introduce a urine-based liquid biopsy approach that reshapes how treatment response in NMIBC is assessed. They use urine tumor DNA to detect minimal residual disease and disentangle the contributions of surgery and immunotherapy to disease control, with implications extending beyond bladder cancer.